KD Logo

Inozyme Pharma Inc (INZY) receives a Buy rating from Jefferies

Inozyme Pharma Inc’s recently made public that its CEO Treco Douglas A unloaded Company’s shares for reported $52210.0 on Apr 02 ’24. In the deal valued at $6.94 per share,7,523 shares were sold. As a result of this transaction, Treco Douglas A now holds 20,665 shares worth roughly $91132.65000000001.

Then, Hopfner Robert Lorne bought 833,333 shares, generating $3,999,998 in total proceeds. Upon buying the shares at $4.80, the Director now owns 2,923,110 shares.

Before that, Pivotal bioVenture Partners Fu bought 833,333 shares. Inozyme Pharma Inc shares valued at $3,999,998 were divested by the Director at a price of $4.80 per share. As a result of the transaction, Pivotal bioVenture Partners Fu now holds 2,923,110 shares, worth roughly $12.89 million.

Jefferies upgraded its Inozyme Pharma Inc [INZY] rating to a Buy from a a Hold in a research note published on March 23, 2023; the price target was increased to $6 from $4.50. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late May with a ‘”a Hold”‘ rating. H.C. Wainwright began covering INZY with “Buy” recommendation on February 07, 2022. Needham started covering the stock on November 29, 2021. It rated INZY as “a Buy”.

Price Performance Review of INZY

On Tuesday, Inozyme Pharma Inc [NASDAQ:INZY] saw its stock fall -0.23% to $4.41. Over the last five days, the stock has gained 0.23%. Inozyme Pharma Inc shares have risen nearly 3.52% since the year began. Nevertheless, the stocks have fallen -19.96% over the past one year. While a 52-week high of $7.80 was reached on 04/01/24, a 52-week low of $2.69 was recorded on 01/17/24. SMA at 50 days reached $5.75, while 200 days put it at $4.72. A total of 0.64 million shares were traded, compared to the trading of 0.58 million shares in the previous session.

Levels Of Support And Resistance For INZY Stock

The 24-hour chart illustrates a support level at 4.34, which if violated will result in even more drops to 4.28. On the upside, there is a resistance level at 4.51. A further resistance level may holdings at 4.62. The Relative Strength Index (RSI) on the 14-day chart is 32.90, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.18, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.44%. Stochastics %K at 17.66% indicates the stock is a buying.

The most recent change occurred on August 18, 2020 when Wedbush began covering the stock and recommended ‘”an Outperform”‘ rating along with a $35 price target.

Most Popular

[the_ad id="945"]